Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 29(2024), 3 vom: 25. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Bo-Wen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Retroviral Agents |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules29030598 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368278360 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368278360 | ||
| 003 | DE-627 | ||
| 005 | 20240214233318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules29030598 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368278360 | ||
| 035 | |a (NLM)38338343 | ||
| 035 | |a (PII)598 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Bo-Wen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a molecule inhibitor | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 4 | |a respiratory syncytial virus (RSV) | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Palivizumab |2 NLM | |
| 650 | 7 | |a DQ448MW7KS |2 NLM | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Zhang, Peng-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zong-Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a He, Meng-Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Rui-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Che, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Zi |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xiang-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Li-Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 29(2024), 3 vom: 25. Jan. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:3 |g day:25 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules29030598 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 3 |b 25 |c 01 | ||